Antibody Discovery & Development Strategies 2012
October 11 - 12, 2012
Delegates will attend this program to learn about the latest advancements in antibody discovery and development, including cutting-edge research on how to identify the correct target for an antibody, and how to streamline the entire development process to get more products out and reduce budget needs.
Attendees will also hear about hot topics such as bispecifics and the latest advancements in antibody drug conjugates (ADCs) and their impact on certain critical therapeutic areas. Key to the conference will be addressing a need for quality antibodies and learning about what leading companies such as Genentech, Bayer, Intrexon and Merck are producing in the way of new antibody treatments.
• keynote speakers
Lihui Xu,David Meininger, Ph.D., M.B.A.,Mitchell Ho, Ph.D.,Andrew E. Nixon, Ph.D
key conference topics
• Improving research tactics to help produce robust antibody candidates for critical therapeutic areas
• Considering novel areas to explore, including antibody drug conjugates (ADCs) and bispecifics
• Investing in new technologies and equipment to streamline the screening, purification and development processes
• Overcome challenges in identifying the best target for an antibody
• Building a relationship between academia and biopharmaceutical companies to collaborate on discovery and early research of antibody candidates
Attendees will also hear about hot topics such as bispecifics and the latest advancements in antibody drug conjugates (ADCs) and their impact on certain critical therapeutic areas. Key to the conference will be addressing a need for quality antibodies and learning about what leading companies such as Genentech, Bayer, Intrexon and Merck are producing in the way of new antibody treatments.
• keynote speakers
Lihui Xu,David Meininger, Ph.D., M.B.A.,Mitchell Ho, Ph.D.,Andrew E. Nixon, Ph.D
key conference topics
• Improving research tactics to help produce robust antibody candidates for critical therapeutic areas
• Considering novel areas to explore, including antibody drug conjugates (ADCs) and bispecifics
• Investing in new technologies and equipment to streamline the screening, purification and development processes
• Overcome challenges in identifying the best target for an antibody
• Building a relationship between academia and biopharmaceutical companies to collaborate on discovery and early research of antibody candidates
Venue
Sorry, this event is quite new so we couldn't find any venue information.
Please check again in the near future.
Please check again in the near future.
Related events
Antibody Discovery & Development Strategies October 11 - 12, 2012
